Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 16Colonic Neoplasms 11Rectal Neoplasms 8Head and Neck Neoplasms 7Neoplasm Metastasis 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Chordoma 2Breast Neoplasms 2Unresectable Colorectal Cancer 1Tongue Neoplasms 1Thymoma 1Solid Tumor, Adult 1Solid Cancer 1Skin Neoplasms 1Rectal Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Noonan Syndrome 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1

Interventions

venetoclax 1pembrolizumab 1niraparib 1ibrutinib 1encorafenib 1copanlisib 1capivasertib 1RNA-Seq 1Nivolumab 1Interleukin-2 1Gemtuzumab 1Fulvestrant 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Disease Progression × Cetuximab × Clear all
NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡